Want to see HK:2181 full AI Analyst Report?
2181 Stock Chart & Stats
HK$0.50
>-HK$0.01(-1.85%)
At close: 4:00 PM EST
HK$0.50
>-HK$0.01(-1.85%)
Day’s Range― - ―
52-Week RangeHK$0.31 - HK$0.88
Previous CloseN/A
Volume6.00K
Average Volume (3M)354.33K
Market Cap
HK$1.65B
Enterprise ValueHK$1.59B
Total Cash (Recent Filing)HK$109.30M
Total Debt (Recent Filing)HK$326.88M
Price to Earnings (P/E)25.3
Beta0.92
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding4,124,080,000
10 Day Avg. Volume54,400
30 Day Avg. Volume354,333
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)11.77
Price to Sales (P/S)2.94
P/FCF Ratio-79.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained gross margins near 72%–86% indicate durable product economics and pricing power typical of biologics. High gross margins provide structural capacity to fund R&D and scale manufacturing, supporting long-term profitability if SG&A and R&D are managed.
Revenue Growth & Profitability TurnaroundA marked revenue inflection and return to net income show the business moving from development-stage losses to commercial traction. This trend, if maintained by product adoption and sales execution, materially improves solvency and the firm's ability to self-fund growth over the medium term.
Biologics R&D And Manufacturing CapabilityOwning both R&D and manufacturing for mAbs is a strategic advantage in biologics: it shortens time to market, secures supply, and enables higher margins. This integrated capability supports long-term partnerships and commercial scale benefits versus pure-play developers.
Bears Say
Elevated Financial LeverageHigh and rising leverage reduces financial flexibility and raises refinancing and interest-rate risk. With equity small relative to debt, shocks to revenue or cash flow would more quickly impair solvency and constrain strategic choices like M&A, capex or dividend initiation.
Negative Free Cash FlowNegative free cash flow despite positive operating cash indicates heavy capex or working-capital needs. That weak cash conversion limits ability to deleverage or self-fund growth and may force reliance on external financing, heightening long-term funding risk.
Thin Operating ProfitabilityAn EBIT margin near 0.7% leaves little buffer against cost inflation or sales volatility. Converting high gross margins into durable operating profit requires sustained scale or expense control; otherwise the company remains vulnerable despite positive net income.
Mabpharm Limited News
2181 FAQ
What was Mabpharm Limited’s price range in the past 12 months?
Mabpharm Limited lowest stock price was HK$0.31 and its highest was HK$0.88 in the past 12 months.
What is Mabpharm Limited’s market cap?
Mabpharm Limited’s market cap is HK$1.65B.
When is Mabpharm Limited’s upcoming earnings report date?
Mabpharm Limited’s upcoming earnings report date is Aug 21, 2026 which is in 12 days.
How were Mabpharm Limited’s earnings last quarter?
Mabpharm Limited released its earnings results on Mar 26, 2026. The company reported HK$0.014 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.014.
Is Mabpharm Limited overvalued?
According to Wall Street analysts Mabpharm Limited’s price is currently Overvalued.
Does Mabpharm Limited pay dividends?
Mabpharm Limited does not currently pay dividends.
What is Mabpharm Limited’s EPS estimate?
Mabpharm Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mabpharm Limited have?
Mabpharm Limited has 4,124,080,000 shares outstanding.
What happened to Mabpharm Limited’s price movement after its last earnings report?
Mabpharm Limited reported an EPS of HK$0.014 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Mabpharm Limited?
Currently, no hedge funds are holding shares in HK:2181
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mabpharm Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
77.77%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
18.80%
Trailing 12-Months
Company Description
Mabpharm Limited
Mabpharm Limited is a Chinese biopharmaceutical firm dedicated to the research, development, and manufacturing of innovative and biosimilar medications. Its therapeutic focus areas include allergic conditions, various cancers, and autoimmune disorders. The company boasts a robust pipeline, with several key products currently in advanced Phase III clinical trials. These include CMAB007, a recombinant humanized anti-IgE monoclonal antibody targeting asthma; CMAB009, a recombinant anti-EGFR chimeric monoclonal antibody for the initial treatment of metastatic colorectal cancer; CMAB008, a recombinant anti-TNF-alpha chimeric monoclonal antibody designed for moderate to severe active rheumatoid arthritis; and CMAB807, an agent developed for osteoporosis. Furthermore, Mabpharm is progressing various candidates through Phase I clinical development. Among these are CMAB819, aimed at treating metastatic non-small cell lung cancer, hepatocellular carcinoma, and head and neck squamous cell carcinomas; CMAB807X, formulated for tumor bone metastasis; and CMAB809, which targets HER2 overexpressing breast cancer and metastatic gastric cancer. The preclinical pipeline is equally extensive, featuring CMAB810 for breast cancer; CMAB816, addressing periodic fever syndrome, lung cancer, and systemic juvenile idiopathic arthritis; and CMAB017, intended for KRAS wild-type colorectal cancer. Also in preclinical stages are biosimilar candidates such as CMAB015, an analog of secukinumab for plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis; CMAB018, a mepolizumab biosimilar for asthma and eosinophilic granulomatous polyangiitis; and CMAB022, designed for various inflammatory conditions. Beyond its product development, Mabpharm provides a range of related services, including contract research and development, technical consultation, technology transfer, and specialized technical support for biological products, diagnostic and chemical biological reagents, and pharmaceutical compounds. Established in 2018, Mabpharm Limited is headquartered in Taizhou, People's Republic of China.
Technical Analysis
Alphamab Oncology
―
RemeGen Co. Ltd. Class H
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―
SinoMab Bioscience Ltd.
―